Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,364,099
  • Shares Outstanding, K 74,154
  • Annual Sales, $ 301,030 K
  • Annual Income, $ -361,920 K
  • 60-Month Beta 2.12
  • Price/Sales 38.65
  • Price/Cash Flow N/A
  • Price/Book 8.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.08
  • Number of Estimates 8
  • High Estimate -0.89
  • Low Estimate -1.34
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -63.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.06 +27.64%
on 06/17/19
158.80 -3.49%
on 07/15/19
+33.68 (+28.17%)
since 06/14/19
3-Month
111.09 +37.95%
on 06/03/19
158.80 -3.49%
on 07/15/19
+31.66 (+26.04%)
since 04/16/19
52-Week
95.21 +60.96%
on 12/24/18
165.87 -7.61%
on 10/01/18
+16.57 (+12.12%)
since 07/16/18

Most Recent Stories

More News
Sarepta Therapeu Rises 3.00% on Heavy Volume: Watch For Potential Pullback

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $151.48 to a high of $155.58. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high...

SRPT : 153.25 (-2.33%)
Sarepta Therapeu Up 20.2% Since SmarTrend Uptrend Call (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on June 17th, 2019 at $124.02. In approximately 3 weeks, Sarepta Therapeu has returned 20.17% as of today's recent price of $149.04.

SRPT : 153.25 (-2.33%)
Sarepta Stock Up Almost 40% This Year So Far: Here's Why

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

SRPT : 153.25 (-2.33%)
AYTU : 1.82 (+2.82%)
BMRN : 82.37 (-1.93%)
AXGT : 7.60 (+3.26%)
Sarepta Therapeu Has Returned 26.3% Since SmarTrend Recommendation (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on June 17th, 2019 at $124.02. In approximately 2 weeks, Sarepta Therapeu has returned 26.26% as of today's recent price of $156.60.

SRPT : 153.25 (-2.33%)
Sarepta Therapeu Rises 3.06% on Heavy Volume: Watch For Potential Pullback

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $128.84 to a high of $156.60. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high...

SRPT : 153.25 (-2.33%)
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

SLDB : 5.14 (-2.10%)
SRPT : 153.25 (-2.33%)
WVE : 26.97 (-0.11%)
PFE : 42.85 (+0.23%)
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

PTCT : 42.99 (-1.44%)
SLDB : 5.14 (-2.10%)
SRPT : 153.25 (-2.33%)
PFE : 42.85 (+0.23%)
Shares of Pfenex Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PFNX, SRPT , CLVS , NVTA , TGTX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SRPT : 153.25 (-2.33%)
PFNX : 5.90 (-5.45%)
CLVS : 12.80 (-1.23%)
Stocks Soar 7% in June

Stocks Soar 7% in June

NVTA : 22.52 (-0.79%)
DERM : 8.67 (+0.70%)
SRPT : 153.25 (-2.33%)
RCII : 27.49 (-1.08%)
EDIT : 24.33 (-3.83%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019, that were previously approved by the Compensation Committee...

SRPT : 153.25 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 159.42
1st Resistance Point 156.34
Last Price 153.25
1st Support Level 151.16
2nd Support Level 149.06

See More

52-Week High 165.87
Last Price 153.25
Fibonacci 61.8% 138.88
Fibonacci 50% 130.54
Fibonacci 38.2% 122.20
52-Week Low 95.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar